Request Demo
Last update 25 Oct 2025
Dapagliflozin/Metformin Hydrochloride/Saxagliptin Hydrochloride
Last update 25 Oct 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Dapagliflozin/Saxagliptin/Metformin hydrochloride, Metformin Hydrochloride/Saxagliptin/Dapagliflozin, metformin hydrochloride/Saxagliptin/dapagliflozin + [2] |
Target |
Action inhibitors, activators |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (02 May 2019), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H27N3O3 |
InChIKeyAFNTWHMDBNQQPX-NHKADLRUSA-N |
CAS Registry945667-22-1 |
View All Structures (3)
Related
1
Clinical Trials associated with Dapagliflozin/Metformin Hydrochloride/Saxagliptin HydrochlorideNCT03169959
A Randomised, 3-Period, 3-Treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin / 10 mg Dapagliflozin / 1000 mg Metformin XR Relative to Individual Components (Onglyza® and XIGDUO® XR) Co-administered to Healthy Subjects
100 Clinical Results associated with Dapagliflozin/Metformin Hydrochloride/Saxagliptin Hydrochloride
Login to view more data
100 Translational Medicine associated with Dapagliflozin/Metformin Hydrochloride/Saxagliptin Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dapagliflozin/Metformin Hydrochloride/Saxagliptin Hydrochloride
Login to view more data
100 Deals associated with Dapagliflozin/Metformin Hydrochloride/Saxagliptin Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | United States | 02 May 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free